Correction to: Nature Cancer https://doi.org/10.1038/s43018-022-00398-7, published online 17 June 2022.
In the version of this article initially published, salient aspects of patient outcomes were not clearly articulated in the abstract, which has now been revised to include the text “Within 4 weeks after vaccination, serious adverse events occurred in eight patients (12.5% 95% CI 5.6–23%): six patients were hospitalized due to events common under cancer therapy including immune related adverse events and two patients died due to conditions present before vaccination”. The changes have been made in the HTML and PDF versions of the article.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Walle, T., Bajaj, S., Kraske, J.A. et al. Author Correction: Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy. Nat Cancer 3, 1137 (2022). https://doi.org/10.1038/s43018-022-00420-y
Published:
Issue date:
DOI: https://doi.org/10.1038/s43018-022-00420-y
